Allogeneic transplantation: A therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia

Bone Marrow Transplantation

Volumn 33, Issue 10, 2004, Pages 1005-1009

  Mittal, P ^a   Saliba, R M ^a   Giralt, S A ^a   Shahjahan, M ^a   Cohen, A I ^a   Karandish, S ^a   Onida, F ^a   Beran, M ^a   Champlin, R E ^a   de Lima, M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic myelomonocytic leukemia; CML; Myelofibrosis; Myeloproliferative diseases; Philadelphia chromosome BCR ABL negative

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; IDARUBICIN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; PENICILLIN G; QUINOLINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; DRUG BLOOD LEVEL; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PATIENT SELECTION; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; RELATIVE; SURVIVAL TIME; TREATMENT PLANNING;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FUSION PROTEINS, BCR-ABL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MYELOFIBROSIS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 2942585719     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704472     Document Type: Article

References (29)

1. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classication of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie house, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
2. Montefusco E, Alimena G, Coco L et al. Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome. Ann Hematol 1992; 65: 17-21.
3. Kantarjian HM, Kurzrock R, Talpaz M. Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Hematol/Oncol Clin N Am 1990; 4: 389-404.
4. Hessling J, Kroger, Werner M et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119: 769-772.
5. Przepiorka D, Giralt S, Khouri I et al. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998; 57: 24-28.
6. Anderson JE, Sale G, Appelbaum FR et al. Allogeneic marrow transplantation for primary myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 1997; 98: 1010-1016.
7. Singhal S, Powles R, Treleaven J et al. Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 1995; 16: 743-746.
8. Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220-226.
9. O'Donnell MR, Nademanee AP, Snyder DS et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987; 5: 1822-1826.
10. Guardiola P, Esperou H, Cazals-Hatem D et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol 1997; 98: 1004-1009.
11. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
12. Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Prentice RL, Kalbfleisch JD. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541-554.
15. Dupriez B, Morel P, Demory JL et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013-1018.
16. Reilly JT. Pathogenesis and management of idiopathic myelofibrosis. Bailliere's Clin Haematol 1998; 11: 751-767.
17. Rajantie J, Sale GE, Deeg HJ et al. Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood 1986; 67: 1693-1697.
18. Creemers GJ, Lowenberg B, Hagenbeek A. Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1992; 82: 772-773.
19. Soll E, Massumoto C, Clift RA et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995; 86: 4667-4673.
20. Onida F, Kantarjian HM, Smith TL et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840-849.
21. Fenaux P, Beuscart R, Lai JL et al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 1998; 6: 1417-1424.
22. Tefferi A, Hoagland HC, Therneau TM, Pierre RV. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc 1989; 64: 1246-1254.
23. Wattel E, Guerci A, Hecquet B et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 1996; 88: 2480-2487.
24. Beran M, Kantarjian H, O'Brien S et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996; 88: 2473-2479.
25. Zang DY, Deeg HJ, Gooley T et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. Br J Haematol 2000; 110: 217-222.
26. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
27. Storb RF, Champlin R, Riddell SR et al. Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Progr) 2001; 375-391.
28. Champlin R, Khouri I, Shimoni A et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18-29.
29. Devine SM, Hoffman R, Verma A et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255-2258.